FIG. 7.

The effect of DATS combined with DOC on the growth of BGC823 xenograft tumors. Tumorigenicity was examined by subcutaneous injection of BGC823 into nude mice. The mice with tumor xenografts of ∼100 mm³ in size at day 6 were treated with DATS (i.p., 20 mg/kg) and/or DOC (i.p., 10 mg/kg) twice per week. Tumor volume of BGC823 xenograft and body weight of the mice were measured every 3 days until the animals were sacrificed at day 42. (A) Tumor volume measured at the indicated times, (B) weight of the xenograft tumors isolated at day 42. (C) Body weight of tumor-bearing mice measured at the indicated times. Results shown represent the mean ± standard deviation, n = 2 flanks ×3 mice in each group, *p < 0.05, **p < 0.01, significant differences from the control. (D) Immunohistochemical staining of isolated BGC823 xenograft tumors. Brown staining indicates the expression of MT2A, IκB-α, p-IκB-α, CCND1, CCNB1, or a-CASP3, respectively. Magnifications: ×200. i.p., intraperitoneal injection. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars